Journals / Glokom Katarakt / 2011 / Cilt: 6 - Sayı: 4

Efficacy of prostaglandin analogs

Prostaglandin analoglarının etkinliği

Pages
246–249
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: According to this study, all 3 prostaglandin analog therapies were found to have similar efficacy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Intraocular pressure lowering efficacy of prostaglandin analog therapy have been studied in this study.
📊
Key Findings & Data:Materials and Methods: 30 eyes of 15 patients using Latanoprost, 28 eyes of 14 patients using Travoprost and 20 eyes of 10 patients using Bimatoprost with diagnosis of glaucoma or ocular hypertension are included in this study.
💡
Conclusion & Impact:Conclusions: According to this study, all 3 prostaglandin analog therapies were found to have similar efficacy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: Intraocular pressure lowering efficacy of prostaglandin analog therapy have been studied in this study. Materials and Methods: 30 eyes of 15 patients using Latanoprost, 28 eyes of 14 patients using Travoprost and 20 eyes of 10 patients using Bimatoprost with diagnosis of glaucoma or ocular hypertension are included in this study. The control examinations and intraocular pressure measurements are done at the 1st, 3rd and 6th months of treatment. Results: 56.4%of patients included in the study was female and 43.6%was male. The mean age of the patiens was 54.08 years. No difference was found between the groups in the intraocular lowering efficacy. Conclusions: According to this study, all 3 prostaglandin analog therapies were found to have similar efficacy.

Özet

Amaç: Bu çalışmada, prostaglandin analoglarının göz içi basıncını (GİB) düşürmedeki etkinlikleri incelendi. Gereç ve Yöntem: Çalışmaya glokom veya oküler hipertansiyon tanısı konulmuş, Latanoprost kullanan 15 hastanın 30 gözü, Travoprost kullanan 14 hastanın 28 gözü ve Bimatoprost kullanan 10 hastanın 20 gözü dahil edildi. Çalışmaya dahil edilen tüm hastalar tedavinin 1., 3. ve 6. ayında kontrole çağrıldı, GİB ölçümü ve ayrıntılı oftalmolojik muayeneleri yapıldı. Bulgular: Çalışmaya dahil edilen hastaların %56.4'ü kadın (n=22), %43.6'sı erkek (n=17) idi. Yaş ortalamaları 54.08±11.57 idi (21-78 aralığında). Cinsiyet ve yaş ortalaması açısından 3 ilaç grubu birbirleriyle benzerdi. Üç ilaç arasında GİB düşürücü etkinlik açısından aralarında anlamlı bir fark saptanmadı. Sonuç: Bu çalışmada glokom tedavisinde kullanılan ve prostaglandin analoğu olan her 3 ilacın da benzer etkinliği olduğu izlenmiştir.

🔖

Cite This Article

ÜN, Y., TETİKOĞLU, M., YILMAZ, F. S. O., ÖZTÜRK, M., ELÇİOĞLU, M. (2011). Efficacy of prostaglandin analogs. Glokom Katarakt, Cilt: 6 - Sayı: 4, 246–249. https://ajindex.com/articles/226508

References (15)

  1. Kroese N, Burton H, Vordy S, et al.: Prevalence of primary open angle glaucoma in the United Kingdom. Br J Ophthalmol. 2002;86:987-990
  2. Anton A, Andrate MT, Mujice V, et al.: Prevalence of open angle glaucoma in a Spanish population. J Glaucoma. 2004;13:371-376
  3. Friedman DS, Jampel HD, Monoz B, et al.: The Prevalence of open angle glaucoma among blacks and whites 73 years and older:the Salisbury Eye Evaluation Glaucoma Study. Arch Ophthalmol. 2006;124:1625-1630
  4. European Glaucoma Society.: Glokom için terminoloji ve rehber (3. Basım). DOGMA S.r.l, Sanova, Italy. 2009
  5. Kanner E, Tsai JC.: Glaucoma medications: use and safety in the elderly population. Drugs Aging. 2006;23:321-332
  6. Torris CB, Camras CB, Yablonski ME.: Effects of PhXA41,a PGF2α analogue, on aqueus humor dynamics in human eyes. Ophthalmology. 1993;100:1297-1304
  7. Sihota R, Saxena R, Agarwal HC, et al.: Crossover comparison of Timolol and Latanoprost in chronic primary angle-closure glaucoma. Arch Ophthalmol. 2004;122:185-189
  8. Camros CB., United States Latanoprost Study Group.: Comparison of Latanoprost and Timolol in patients with ocular hypertension and glaucoma. A six month, masked, multi center trial in the United States. Ophthalmology. 1996;103:138-147
  9. Watson P, Stjernschanz J, Latanoprost Study Group.: A six month randomized double masked study comparing to Timolol in open angle glaucoma and ocular hypertension. Ophthalmology. 1996;103:126-137
  10. Parrish RK, Palmberg P, Sheu WP.: A comparison of Latanoprost, Bimatoprost, and Travoprost in patients with elevated intraocular pressure: a 12 week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688-703
  11. Przydryga JT, Egloff C, and Swiss Start Study group.: Intraocular pressure lowering efficacy of Travoprost. Eur J Ophthalmol. 2004,14:416-422
  12. Netland PA, Landry T, Sullivan EK, et al.: Travoprost compared with Latanoprost and Timolol in patients with open angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472-484
  13. Brubaker RF.: Mechanism of action of Bimatoprost (Lumigan). Surv Ophthalmol. 2001;45:347-352
  14. Higginbotham EJ, Schuman JS, Goldberg I, et al.: One year randomized study comparing Bimatoprost and Timolol in glaucoma and ocular hypertension. Arch Ophthalmol.120:1286-1293
  15. Noecker RJ, Dirsks MS, Choplin NT, et al.: A six month randomized clinical trial comparing the intraocular pressure lowering efficacy of Bimatoprostand Latanoprost in patients wi